The Outlook for CAR-Modified T Cells

Special Reports, Immunotherapy (Issue 2), Volume 2, Issue 1

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.

Renier J. Brentjens, MD, PhD, associate professor, chief, Cellular Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses the outlook for CAR-modified T cells.

Read more about CAR-modified T cells and other immunotherapies for B-cell malignancies > >